Panobinostat Recaptured Response in Bortezomib-Refractory Myeloma Patients

The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib helped to elicit responses in about one-third of heavily pre-treated patients with multiple myeloma who were refractory of bortezomib, according to the phase II results of the PANORAMA 2 study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news